Trump Ousts FDA Commissioner Makary in Regulatory Overhaul Push

The practical consequences are already visible. Makary had staked out positions on accelerated drug approvals and expanded access pathways, approaches that pharmaceutical and medical device companies had begun building into their go-to-market timelines for 2026 and 2027 launches . An abrupt leadership change means those timelines are now assumptions, not facts. FDA leadership transitions historically slow the pace of new drug application reviews during the first 90 to 180 days of a new commissioner's tenure, as incoming leadership reviews staff priorities and pending decisions , a pattern documented across multiple transitions since 2000 . For any brand team managing a product launch in Q3 or Q4 2026, that gap is a marketing crisis hiding in plain sight.

The FDA does not merely regulate what drugs reach market. It governs what marketers can say about those drugs, how they can say it, and to whom. Every direct-to-consumer television spot, every physician-facing detail aid, every sponsored social post about a prescription therapy operates under FDA's Office of Prescription Drug Promotion oversight. When leadership priorities shift, enforcement emphasis shifts with them. Healthcare marketers who built 2026 campaigns on assumptions about what the FDA would , and would not , scrutinize owe it to their organizations to pressure-test those assumptions today, not at the next legal review cycle.

What a Lame-Duck FDA Looks Like for Product Launch Teams

An FDA in transition is an FDA that moves slower and signals less. Without a confirmed commissioner, career staff at CDER and CDRH operate with reduced political cover to make discretionary calls on borderline promotional materials, label expansions, and indication updates. The result is predictable: review timelines extend, warning letters slow, and then accelerate in bursts as a new commissioner establishes credibility by demonstrating enforcement activity.

Drug and device marketers should treat the period between commissioners as a yellow light, not a green one. Campaigns built around claims that rest on pending FDA guidance documents , rather than already-cleared language , carry elevated risk. A claim that a sympathetic commissioner's team might have reviewed permissively will face stricter scrutiny from a new team eager to demonstrate independence. Our recommendation at 1ness: audit every active promotional piece against its underlying regulatory basis before a new commissioner is confirmed. Identify which claims depend on guidance documents, which rest on approved labeling, and which exist in the grey zone. Prioritize the grey zone for legal review now, before enforcement priorities crystallize.

The DTC Ad Market Hangs in the Balance

Direct-to-consumer pharmaceutical advertising is a $7.5 billion annual market in the United States . It operates under a framework that the FDA has periodically threatened to revise , most recently through the Biden administration's 2024 proposed rules on television ad disclosures , and that has been on the Trump administration's regulatory reform radar as part of broader healthcare cost reduction efforts. Makary's removal injects new uncertainty into where those proposals land.

For health system marketers and pharmaceutical brand teams alike, the uncertainty cuts two ways. A more permissive successor could ease restrictions on digital DTC formats , programmatic video, connected TV, influencer partnerships with physicians , that have existed in a compliance grey zone for years. A more restrictive one could accelerate demands for clearer risk disclosures in digital formats, where the FDA's existing guidance dates to 2014 and has not kept pace with the TikTok and YouTube ecosystem. Either outcome reshapes budget allocations. Neither outcome can be ignored.

Healthcare system marketers , who do not run FDA-regulated prescription drug ads but do compete for the same consumer attention , benefit from watching this carefully. Reduced DTC spending from pharma during a regulatory pause typically increases the relative effectiveness of health system brand advertising, as consumer healthcare attention becomes less contested. During the 2009 FDA review of DTC guidelines, health system and insurance brand recall scores rose measurably in markets where pharma DTC volume dropped .

Physician Marketing Faces Its Own Recalibration

Makary's tenure included signals of interest in transparency around physician-industry relationships, building on the Open Payments database that CMS administers but that the FDA influences through its promotional compliance framework. Medical device and pharmaceutical companies that market through physician education programs, speaker bureaus, and clinical advisory boards should flag that a new commissioner may revisit how promotional education events are classified and disclosed.

This is not hypothetical risk. The DOJ's 2023 and 2024 settlements with multiple medical device manufacturers , including cases involving promotional practices disguised as medical education , demonstrated that enforcement in this space has teeth and dollar consequences that reach nine figures . A new FDA leadership team looking to establish credibility will find physician marketing compliance an attractive target: it is visible, politically legible, and generates headlines. Marketers who run CME programs, advisory board meetings, or sponsored symposia should conduct a line-by-line review of how those activities are documented and disclosed.

Actionable Takeaways for Healthcare Marketing Leaders

• Freeze grey-zone claims. Any promotional claim resting on pending guidance, not approved labeling, should be flagged for legal review before a new commissioner is named.
• Build contingency timelines. Product launch calendars should include a 90-day buffer for any launch dependent on FDA action in 2026. Assign a scenario owner to track nomination and confirmation proceedings.
• Audit physician programs now. Review all speaker bureau, advisory board, and CME-adjacent programs against current Open Payments disclosure requirements and document the compliance basis for each.
• Monitor DTC budget signals. Track pharma DTC spend in your markets using tools like MediaRadar or Vivvix. A reduction in category DTC volume is an opportunity to increase health system or competing brand SOV.
• Reassess digital compliance posture. If your social or digital campaigns involve prescription product promotion, identify which pieces rely on 2014-era FDA digital guidance. Those pieces carry elevated risk in any regulatory reset.

Compliance Callout

The 1ness Take

The instinct during regulatory uncertainty is to wait , to hold campaigns, delay launches, and see who the next commissioner is before making decisions. That instinct is wrong, and it is expensive.

The healthcare marketers who win during FDA transitions are the ones who use the pause productively. They clean up their compliance documentation. They build the scenario models their competitors won't build until Q4. They identify which product claims are bulletproof and amplify those, while pulling back on the claims that need a sympathetic regulator to survive scrutiny.

More strategically: this transition is a forcing function for something healthcare marketing has needed for years , a clear-eyed audit of where your promotional claims rest on regulatory sand versus bedrock. Most healthcare brand teams cannot answer that question without calling legal. After this article, you should be able to answer it yourself.

At 1ness, our position is clear: regulatory volatility is not a reason to go dark. It is a reason to be the most compliance-credible voice in your category. Brands that demonstrate rigor during a regulatory transition earn a trust premium with physicians, health systems, and patients that outlasts any individual commissioner's tenure. The organizations that treat this moment as a compliance audit opportunity , not a pause button , will enter the next regulatory regime ahead.

The Takeaway

1. This week: Convene your regulatory, legal, and marketing leads for a 60-minute audit of every active campaign's compliance basis. Flag any claim resting on pending FDA guidance.

2. This month: Build a 90-day contingency buffer into every 2026 product or service launch timeline that depends on FDA action, and assign a named owner to track the commissioner nomination process.

3. This quarter: Commission a formal review of your physician marketing and education programs against current Open Payments and FDA promotional standards , before a new commissioner makes that review involuntary.